What's new? Log in Free sign up

Corbus Pharmaceuticals (CRBP)

Company Profile

Company profile

Ticker

CRBP

Exchange

Website

www.corbuspharma.com

CEO

Dr. Yuval Cohen Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

SAV Acquisition Corp

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Corbus Pharmaceuticals, Inc. • Corbus International Limited • Corbus Pharmaceuticals Australia Pty Ltd ...

CRBP stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Quarterly report

7 Nov 24

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Regulation FD Disclosure

Quarterly report

6 Aug 24

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

ORBIMED ADVISORS LLC

Notice of proposed sale of securities

Notice of proposed sale of securities

Dominic Smethurst

Point72 Asset Management, L.P.

ORBIMED ADVISORS LLC

Financial summary

Financial statements Chart CRBP financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	20.09 mm	20.09 mm	20.09 mm	20.09 mm	20.09 mm	20.09 mm
Cash burn (monthly)	1.42 mm	(no burn)	5.17 mm	3.85 mm	4.65 mm	3.07 mm
Cash used (since last report)	7.13 mm	n/a	25.94 mm	19.33 mm	23.33 mm	15.42 mm
Cash remaining	12.96 mm	n/a	-5.85 mm	761.68 k	-3.23 mm	4.68 mm
Runway (months of cash)	9.1	n/a	-1.1	0.2	-0.7	1.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CRBP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	115	110	+4.5%
Opened positions	34	41	-17.1%
Closed positions	29	18	+61.1%
Increased positions	40	22	+81.8%
Reduced positions	20	24	-16.7%

13F shares	Current	Prev Q	Change
Total value	234.63 bn	461.64 bn	-49.2%
Total shares	14.19 mm	12.99 mm	+9.2%
Total puts	838.00 k	30.80 k	+2620.8%
Total calls	579.20 k	22.40 k	+2485.7%
Total put/call ratio	1.4	1.4	+5.2%

Largest owners	Shares	Value	Change
Cormorant Asset Management	2.38 mm	$49.00 bn	+17.3%
Cormorant Global Healthcare Master Fund	1.48 mm	$0.00	0.0%
Octagon Capital Advisors	1.12 mm	$23.00 bn	+128.5%
Orbimed Advisors	912.55 k	$18.83 bn	NEW
BlackRock	802.72 k	$16.56 bn	NEW
Vanguard	645.65 k	$13.32 bn	+10.4%
Tang Capital Management	600.00 k	$12.38 bn	NEW
STT State Street	595.58 k	$12.29 bn	+34.6%
Adage Capital Partners GP, L.L.C.	528.94 k	$10.91 bn	+32.2%
Adage Capital Management	528.94 k	$8.76 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Orbimed Advisors	912.55 k	+912.55 k	NEW
BlackRock	802.72 k	+802.72 k	NEW
BLK BlackRock	0.00	-761.37 k	EXIT
Octagon Capital Advisors	1.12 mm	+627.00 k	+128.5%
Tang Capital Management	600.00 k	+600.00 k	NEW
Adage Capital Management	528.94 k	+528.94 k	NEW
Cormorant Asset Management	2.38 mm	+350.00 k	+17.3%
K2 HealthVentures Equity Trust	2.87 k	-339.24 k	-99.2%
Citadel Advisors	0.00	-332.76 k	EXIT
Darwin Global Management	0.00	-325.14 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRBP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Feb 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	8.7559	7,134	62.46 k	138,187
14 Feb 25	Sean F. Moran	Common Stock, par value $0.0001 per share	Sell	Dispose S	No	Yes	8.7559	2,792	24.45 k	73,313
31 Jan 25	Cohen Yuval	Common Stock, par value $0.0001 per share	Grant	Acquire A	No	No	0	68,100	0.00	145,321
31 Jan 25	Cohen Yuval	Stock options Common Stock	Grant	Acquire A	No	No	9.79	228,800	2.24 mm	228,800
31 Jan 25	Sean F. Moran	Common Stock, par value $0.0001 per share	Grant	Acquire A	No	No	0	27,500	0.00	76,105
31 Jan 25	Sean F. Moran	Stock options Common Stock	Grant	Acquire A	No	No	9.79	92,500	905.58 k	92,500
31 Jan 25	Dominic Smethurst	Common Stock, par value $0.0001 per share	Grant	Acquire A	No	No	0	27,200	0.00	77,200
31 Jan 25	Dominic Smethurst	Stock options Common Stock	Grant	Acquire A	No	No	9.79	91,200	892.85 k	91,200

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

William Blair Initiates Coverage On Corbus Pharmaceuticals with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform rating.

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $75 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $75 price target.

Cannabis Stock Movers For February 17, 2025

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $75

Press releases

From Benzinga Pro

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that the abstract for its first-in-human dose escalation clinical study

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today announced the

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.